Ben Richardson, CEO at SulNOx, confident they can cost-effectively decarbonise commercial shipping. Watch the video here.
As I said soonbetime, nobody can be 100% certain on the current trial status.
If we were to base our outlook on what has been said in Previous RNSs, then one would deduce that the trials in China started some time ago after it was stated that reagents would be delivered in Q2 2022. This would allow for an initial pilot trial of 300 patients.
Also in one of ASs interviews he stated that he was visiting our Chinese partners around Xmas 2022 and he looked forward to reporting back on progress over there.
Nothing came of either examples.
I quoted the Bio-Techne scenario to highlight how AS updates the market on milestones reached, but if we are to base progress on what has previously been said, then we are in the opinions business as shareholders.
I look forward to announcements on all fronts, and yes, even China.
Do I consider a trial start date as fluff?
No most certainly not.
GL all
VV
Soonbetime,
Unfortunately, there is nobody on here that is able to answer that question with 100% certainty.
Our CEO has gone on record as stating that he won’t announce “Fluff” news.
The platform trials with Bio-Techne as an example were only announced once they were completed.
The quandary therefore is either our CEO determines that announcing the start of the trials is fluff, or they haven’t actually started the trials yet.
My own view is that the start of the trials is material news which certainly cannot be categorised as anything other than material.
I know that this won’t answer your question, but that’s where we find ourselves.
VV
@Mary
I normally don’t wish losses on any retail investor, but a SDRY event would please me no end as it would knock dogger and his sidekick topaz clean off their perch.
I can confirm dogger posts under the name lodgeview on ADVFN.
CA not EC.
Oops.
Thanks for your response Brondby.
It would be good to hear something on the NHS, after an update on the US.
I feel that if we do hear anything regarding the NHS it would have to be some sort of agreement with the likes of Siemens or Abbott regarding initial work on fitting our IP onto their proprietary platforms. This would then allow them to carry out the necessary clinical trials to gain EC and or MHRA approval.
Not sure how long that would take, but I suspect that it would be measured in years, not months.
This would fit in with AS’s licensing model.
Hi Brondby,
I’d be interested to hear what sort of update your thinking of regarding the NHS.
VV
Dug,
It’s highly unlikely that you will obtain the actual email address of the chairman from a cold start for obvious reasons.
The method of your approach can have a greater bearing on how successful you are in at least getting your message through to your target.
I’ve often found the best approach is via an initial phone call explaining that you have some information that you feel would be best addressed to the chairman. You state that you don’t expect the company to give out the chairman’s email, but if they could provide the email address of the chairman’s office like his PA or assistant, then you can send it on to them.
That tends to lower the defensive barriers sometimes.
Whether you get a response from that person via the chairman or even a direct response from the man himself can often be reliant on your message.
Good luck
Both trades are above the bid and the ask so it’s a long.
If it was a short it would be the opposite.
That’s the charge or commission if you like for the CFD provider.
They make their money from the spread and a small percentage of interest.
A rollover is normally a CFD renewal.
A kind of spreadbet but with interest charged.
Love them to be buys but it looks more like a rollover to me.
He posted this earlier today…
Good Afternoon Fellow PFC Shareholders,
I trust you are all keeping well... Based on today's rise the longs I'm sure are... Shorts not so much ;-)
Some positive news Leaked??
Mmmm... We think as much... A share doesn't just randomly jump +23% over a 5 day period for no rhyme or reason...
If possible we would love to hear the thoughts of a few of the long term holders on how they see the next 6 months playing out??
Mary we value your opinion so please let us know your thoughts if you don't mind.
Shorts no doubt you will want to have your say but for the record we are going know where anytime soon so hearing about a capital raise is of no interest to us...
At present the Talisman are divided...
> In my Camp we believe that there is a buyout being negotiated... Our SP Forecast based on our workings where we looked at various different valuation models based on forward earnings & PE ratios of like for like competitors in the market we see fair value at 170p - 200p.
> In Daves Camp they see it playing out as follows:
- News landing shortly on who's been hoovering up all these cheap shares , SP movement forecast+40p
- Shorts panic shortly after, SP movement forecast +50p
- Within the next 2months PFC announce capital safety plan , SP movement forecast +80p
- Gradual incline thereafter based on how Project Pipeline feeds into Debt Reduction , EOY SP Movement +150p
- New Contract Wins will increase these projections
We are very interested to get your thoughts...
PS. for those interested... we are still in the dark on how investigation is proceeding but we have been told it is still under review.
Until next time all...
Onwards and Upwards
It was Talies.
I give up.
Good luck in your shares.
Thank heavens that’s over with.
You’d do better asking your fellow shareholders what they expected.
The comments on here might give you a hint.
Like I said, I’d love for this to succeed for reasons already stated.
It would help if you realised that and weren’t so triggered.
“Nothing unexpected”?
It seems most of your fellow shareholders were expecting a different update last week and what they actually got was…very unexpected.
Me, I’m merely an observer.
@mikey.
I probably fall under the category of new accounts, at least on here anyway.
Whilst this is only my 4th or 5th post on here I stated in my 1st post that I was not a holder and that OBD was on my watchlist, and there it will stay in the short term.
My interest in this share was initially down to its success. (Sp wise)
This interest emanated from the fact that I too am invested in a share that is looking to achieve LDT accreditation in the USA and I wanted to observe the uptake of a disruptive and superior test and validate my investment in another share.
My comments merely reflected the reaction both on here and that of the market in general.
The product is unquestionable, the Management however, isn’t.
It’s easy to see why so many investors were drawn to this company but after the results/webinar, the cold reality of introducing a new, albeit far superior test into the market has highlighted the lack of a pre-planned sales and marketing strategy.
After all of the hubris contained in regulatory news, who would you suggest is at fault for the decline in the sp?
Ps. Not all contrarian views wish a bad outcome for holders on here.
Good luck to you.
Despite JBs egotistical claims that previous fundraisings have been executed at a premium, I think he’ll quickly come to realise after all the “unprecedented demand” hyperbole and a £10m loss, the money men now hold the whip hand.
I can’t believe this man heads the company.